Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Cash from Financing Activities data on file, last reported at $36.2 million in Q2 2026.

• Quarterly Cash from Financing Activities fell 53.35% year-over-year to $36.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$377.0 million (down 246.4% YoY) and the FY2025 annual result came in at -$305.2 million, down 203.75% from the prior year.
• Cash from Financing Activities rose to $36.2 million in Q2 2026, from $15.7 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $297.0 million in Q3 2022 to a low of -$474.3 million in Q3 2025.
• A 5-year average of $35.5 million and a median of $42.3 million in 2023 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 210.08% — and 2025, when it plunged 561.55%.
• Tracing ALNY's Cash from Financing Activities over 5 years: stood at $63.4 million in 2022, then sank by 38.16% to $39.2 million in 2023, then decreased by 20.98% to $31.0 million in 2024, then soared by 46.2% to $45.3 million in 2025, then decreased by 20.04% to $36.2 million in 2026.
• The last three Cash from Financing Activities figures came in at $36.2 million (Q2 2026), $15.7 million (Q1 2026), and $45.3 million (Q4 2025), per Business Quant data.